albiglutide (Tanzeum)
Jump to navigation
Jump to search
Indications
- diabetes mellitus type 2
- for use as monotherapy or in combination with
Contraindications
- personal or family history of
- medullary thyroid carcinoma
- multiple endocrine neoplasia syndrome type 2
Dosage
- once-weekly injectable
Adverse effects
- diarrhea
- nausea
- injection-site reactions
- boxed warning:
- thyroid C-cell tumors (medullary thyroid carcinoma) have been observed in rodent studies with some drugs in this class
Mechanism of action
Notes
- manufactured by GlaxoSmithKline, L.L.C., Wilmington, Del.
More general terms
References
- ↑ Busko M FDA Approves Weekly Injectable Diabetes Drug: Albiglutide Medscape: April 15, 2014 http://www.medscape.com/viewarticle/823645
- ↑ FDA News Release: April 15, 2014 FDA approves Tanzeum to treat type 2 diabetes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393289.htm
- ↑ Prescriber's Letter 21(8): 2014 CHART: Comparison of GLP-1 Agonists Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=300824&pb=PRL (subscription needed) http://www.prescribersletter.com